{
  "metadata": {
    "case_id": 27,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-29T15:28:32.739795",
    "total_alignments": 3,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/27_NCT03052517.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/27_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.7,
          0.3,
          0.2
        ],
        [
          0.4,
          0.8,
          0.3
        ],
        [
          0.1,
          0.25,
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.7,
          "status": "matched",
          "ref_item": {
            "label": "QAW039 150mg",
            "type": "EXPERIMENTAL",
            "description": "QAW039 Dose 1 once daily",
            "interventionNames": [
              "Drug: QAW039 150 mg"
            ]
          },
          "pred_item": {
            "label": "Fevipiprant 150 mg",
            "type": "EXPERIMENTAL",
            "description": "Patients received fevipiprant 150 mg once daily (o.d.) added to standard of care (SoC) asthma therapy.",
            "interventionNames": [
              "Fevipiprant",
              "Standard of Care"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.8,
          "status": "matched",
          "ref_item": {
            "label": "QAW039 450 mg",
            "type": "EXPERIMENTAL",
            "description": "QAW039 Dose 2 once daily",
            "interventionNames": [
              "Drug: QAW039 450 mg"
            ]
          },
          "pred_item": {
            "label": "Fevipiprant 450 mg",
            "type": "EXPERIMENTAL",
            "description": "Patients received fevipiprant 450 mg once daily (o.d.) added to standard of care (SoC) asthma therapy.",
            "interventionNames": [
              "Fevipiprant",
              "Standard of Care"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 2,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "label": "Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Placebo once daily",
            "interventionNames": [
              "Drug: Placebo"
            ]
          },
          "pred_item": {
            "label": "Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Patients received matching placebo once daily (o.d.) added to standard of care (SoC) asthma therapy.",
            "interventionNames": [
              "Placebo",
              "Standard of Care"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.3,
          0.2,
          0.2
        ],
        [
          0.65,
          0.4,
          0.15
        ],
        [
          0.25,
          0.98,
          0.35
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 2,
          "score": 0.2,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "QAW039 150 mg",
            "description": "One tablet of QAW039 150 mg once daily",
            "armGroupLabels": [
              "QAW039 150mg"
            ]
          },
          "pred_item": {
            "type": "OTHER",
            "name": "Standard of Care",
            "description": "Existing asthma therapy according to GINA guidelines (Steps 3, 4, and 5).",
            "armGroupLabels": [
              "Fevipiprant 150 mg",
              "Fevipiprant 450 mg",
              "Placebo"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 0,
          "score": 0.65,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "QAW039 450 mg",
            "description": "One tablet of QAW039 450 mg once daily",
            "armGroupLabels": [
              "QAW039 450 mg"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Fevipiprant",
            "description": "An oral, non-steroidal, highly selective, reversible antagonist of the DP2 receptor administered at doses of 150 mg or 450 mg.",
            "armGroupLabels": [
              "Fevipiprant 150 mg",
              "Fevipiprant 450 mg"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 1,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "One tablet of Placebo once daily",
            "armGroupLabels": [
              "Placebo"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Matching placebo administered once daily.",
            "armGroupLabels": [
              "Placebo"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 6,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.82,
          0.72,
          0.73
        ],
        [
          0.86,
          0.78,
          0.7
        ],
        [
          0.78,
          0.9,
          0.72
        ],
        [
          0.72,
          0.86,
          0.68
        ],
        [
          0.72,
          0.78,
          0.9
        ],
        [
          0.7,
          0.72,
          0.86
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With Treatment Emergent Adverse Events (AEs) up to Week 52 - Cox Regression Model",
            "description": "Adverse events starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +7 days (30 days in the case of a serious AE) were classified as treatment emergent AEs. For this Outcome Measure, AE up to week 52 are reported.",
            "timeFrame": "52 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 1,
          "pred_idx": 0,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With Treatment Emergent Adverse Events (AEs) up to Week 156 - Cox Regression Model",
            "description": "Adverse events starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +7 days (30 days in the case of a serious AE) were classified as treatment emergent AEs",
            "timeFrame": "156 weeks"
          },
          "pred_item": {
            "measure": "Time-to-first treatment emergent adverse event (AE)",
            "description": "AEs (including asthma exacerbations), starting on or after the time of the first intake of study drug and until the day after the last intake of study drug were classified as treatment emergent.",
            "timeFrame": "From first dose up to 52 weeks (Period 1) and optional 104 weeks (Period 2)"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 1,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) up to Week 52 - Cox Regression Model",
            "description": "Serious Adverse events starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +30 days were classified as treatment emergent SAEs. For this Outcome Measure, AE up to week 52 are reported.",
            "timeFrame": "52 weeks"
          },
          "pred_item": {
            "measure": "Time-to-first treatment emergent serious adverse event (SAE)",
            "description": "Assessment of serious adverse events starting on or after the time of the first intake of study drug and until the day after the last intake of study drug.",
            "timeFrame": "From first dose up to 52 weeks (Period 1) and optional 104 weeks (Period 2)"
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) up to Week 156 - Cox Regression Model",
            "description": "Serious Adverse events starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +30 days were classified as treatment emergent SAEs.",
            "timeFrame": "156 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 4,
          "pred_idx": 2,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With Treatment Emergent AEs Leading to Discontinuation From Study Treatment up to Week 52 - Cox Regression Model",
            "description": "Adverse events leading to study treatment discontinuation starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +7 days (30 days in the case of a serious AE) were classified as treatment emergent AEs leading to study treatment discontinuation. For this Outcome Measure, AE up to week 52 are reported.",
            "timeFrame": "52 weeks"
          },
          "pred_item": {
            "measure": "Time-to-first AE leading to discontinuation from study treatment",
            "description": "Assessment of adverse events leading to study treatment discontinuation starting on or after the time of the first intake of study drug and until the day after the last intake of study drug.",
            "timeFrame": "From first dose up to 52 weeks (Period 1) and optional 104 weeks (Period 2)"
          }
        },
        {
          "ref_idx": 5,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With Treatment Emergent AEs Leading to Discontinuation From Study Treatment up to Week 156 - Cox Regression Model",
            "description": "Adverse events leading to study treatment discontinuation starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +7 days (30 days in the case of a serious AE) were classified as treatment emergent AEs leading to study treatment discontinuation",
            "timeFrame": "156 weeks"
          },
          "pred_item": null
        }
      ]
    }
  ]
}